Modernatx Inc.
Patent owner in reexamination·3 ex parte reexams
Modernatx Inc.'s patents have been the subject of 3 USPTO ex parte reexaminations. ExamPat indexes the full prosecution record for each proceeding, including office-action grounds, certificate outcomes, and downstream PTAB and Federal Circuit decisions.
Filings by year
118
219
Outcome track record
How reexams of this owner's patents resolve: claims confirmed, amended, mixed, or fully canceled.
- Certificate outcome split across every bucket
- Claim-survival rate
Defense metrics
Claim-survival rate, average pendency, and the open/closed split across every reexam of this owner's patents.
- Survival rate of closed proceedings
- Average pendency in months
Challengers & examiners
Which requesters most often challenge this owner's patents, and which examiners decide them.
- Top requesters
- Most frequent examiners
Recent reexaminations (3)
| Control # | Filed | Patent | Title | Requester | Status |
|---|---|---|---|---|---|
| 90/014,395 | Oct 24, 2019 | 10,022,435 | Nucleic Acid Vaccines | — | Closed |
| 90/014,394 | Oct 23, 2019 | 9,675,668 | Modified Polynucleotides Encoding Hepatitis A Virus Cellular Receptor 2 | — | Closed |
| 90/014,167 | Aug 17, 2018 | 9,872,900 | NUCLEIC ACID VACCINES | — | Closed |
See the full reexam picture for Modernatx Inc.
Certificate outcomes, pendency, and the parties and examiners behind these cases. Free to sign up.